In Brown et al’s 2020 multicenter trial involving 456 patients, the AE37 arm exhibited comparable disease-free survival (DFS) to the control arm.[11] However, subgroup analyses unveiled potential benefits in advanced-stage, HER2 under-expressed, and triple-negative breast cancer patients. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.